HTB homepage • Conference reports • Articles by subject • Subscribe April 2004 Contents Editorial Volume 5 number 3 April 2004 Treatment alerts Risk factors for severe, life-threatening and fatal hepatotoxicity with nevirapine Conference reports 11th Conference on Retroviruses and Opportunistic Infections (CROI) Drug levels can persist for more than two weeks after stopping efavirenz Race affects absorption and clearance of efavirenz Triple PI interactions: atazanavir increases saquinavir levels in ritonavir-boosted once-daily combination Triple PI interactions: fosamprenavir and Kaletra interaction is difficult to overcome Ribavirin (RBV) does not alter intracellular levels of AZT, 3TC or d4T COLATE study shows no clinical benefit from continuing 3TC to maintain M184V mutation Studies of new pipeline drugs Little benefit seen for treatment during acute infection Summary of resistance studies at Retrovirus Update on peripheral neuropathy in HIV-infection Smoking marijuana provides analgesic effect on HIV neuropathy Two D:A:D updates: cardiovascular risk from HAART, and predictors of hypertension and changes in blood pressure Low-dose rHGH maintains reductions in abdominal fat for 60 weeks Rosiglitazone shows no benefit for lipoatrophy Hypertension related to HAART in HIV-positive women Testosterone therapy for women with low androgen levels or body weight Nevirapine, pregnancy and adverse events Prior nevirapine exposure for pregnant women can contribute to treatment failure Conflicting findings with HAART use in pregnancy and prematurity Antiretrovirals, mode of delivery and transmission risk Tenofovir studies in children Increase of non-AIDS defining cancers in HOPS cohort HIV/HCV coinfection: superiority of pegylated interferon plus ribavirin, but lower response rate compared to mono-infected patients, especially for genotype-1 Epoetin-alfa improves interferon/ribavirin-associated anaemia Antiretrovirals Treatment with generics: tolerability, safety and resistance Gilead discontinues DAPD development Treatment access International community meeting on drug pricing Global Fund halts $92 million grant for Ukraine after problems Global Fund says it needs $5 billion during 2004-2005 South African minister of health in line to chair Global Fund Thai ddI patent case serves as example to other developing countries, Lancet viewpoint piece says UK gives £3 million to WHO’s ‘3 by 5’ treatment goal Hepatitis coinfection International panel issues new guidelines for the care of HIV-HCV coinfected patients NICE approves pegylated interferon plus ribavirin in UK Other news New HIV cases in England and Wales increase by 20% in past year Micronutrient supplements may enhance survival; research has implications for poor countries Durex withdraws N-9 condoms On the web Medical resources PDFs Volume 5 Number 3 April 2004 PDF HTB homepage • Conference reports • Articles by subject • Subscribe
